Pfizer Inc. (NYSE:PFE) Shares Sold by Drucker Wealth 3.0 LLC

Drucker Wealth 3.0 LLC cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 28.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,392 shares of the biopharmaceutical company's stock after selling 28,019 shares during the quarter. Drucker Wealth 3.0 LLC's holdings in Pfizer were worth $1,894,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. purchased a new position in Pfizer in the fourth quarter worth $27,000. Kohmann Bosshard Financial Services LLC purchased a new position in Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the 4th quarter worth $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 1.0%

Pfizer stock traded down $0.23 during trading on Wednesday, reaching $23.38. The company had a trading volume of 12,808,343 shares, compared to its average volume of 40,970,055. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock's 50 day moving average price is $23.28 and its two-hundred day moving average price is $25.12. The firm has a market capitalization of $132.94 billion, a price-to-earnings ratio of 16.59, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.36%. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of research analyst reports. UBS Group increased their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective for the company. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.